Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Immunol Regen Med. 2019 Feb 1;3:26–35. doi: 10.1016/j.regen.2019.01.001

Fig. 5: Secreted products of IL33+ MBV-treated macrophages are myogenic for progenitor cells.

Fig. 5:

(A) Experimental design. C2C12 myoblasts were cultured to confluence and treated with high serum proliferation media, low serum differentiation media, or proliferation media supplemented with media conditioned by st2−/−macrophages stimulated with the indicated test articles (B) Cells were allowed to differentiate and were immunolabeled for sarcomeric myosin. (C) Quantification of myotube formation at day 5 (**indicates p < 0.001; * indicates p < 0.05, error bars represent SEM, n=3 biological replicates analyzed in triplicate).